| Market Cap | $1.98M-90.8% |
| Revenue (ttm) | $535.06K |
| Net Income | -$16.56M |
| EPS | $31.19 |
| Shares Out | 2.39M |
| PE Ratio | 0.03 |
| Forward PE | -0.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,738 |
| Open | $0.86 |
| Previous Close | $0.87 |
| Day's Range | $0.80 - $0.87 |
| 52-Week Range | $0.80 - $16.92 |
| Beta | 0.74 |
| Analysts | none |
| Price Target | $3.00(+261.71%) |
| Earnings Date | n/a |
About DCOY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DCOY stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DCOY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DCOY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DCOY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DCOY Revenue by Segment
| Loss from operations | $3.01M | 60.89% |
| Professional services and Consulting | $810.45K | 16.38% |
| Personnel cost | $695.21K | 14.05% |
| Grant Revenue | $307.43K | 6.21% |
| Facility cost and other | $122.03K | 2.47% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DCOY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DCOY from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from DCOY’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| MEDX | Horizon Kinetics Medical ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
